This New Trial Represents the Third NantCell Study Evaluating Aldoxorubicin Combined with Immunotherapy or Cell-Based Therapy
PR Newswire
LOS ANGELES, June 28, 2018
PR Newswire
LOS ANGELES, June 28, 2018
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey